(Q37762808)

22 August 2017

1 reference

title

New agents and strategies for the hormonal treatment of castration-resistant prostate cancer (English)

1 reference

22 August 2017

1 reference

Nima Sharifi

1

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 July 2010

1 reference

Expert Opinion on Investigational Drugs

22 August 2017

published in

1 reference

22 August 2017

volume

19

1 reference

22 August 2017

issue

7

1 reference

22 August 2017

page(s)

837-846

1 reference

22 August 2017

cites work

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.494178

Clinical practice. Localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.494178

Androgen deprivation therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.494178

Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.494178

The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.494178

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.494178

Persistent intraprostatic androgen concentrations after medical castration in healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.494178

Drug insight: role of the androgen receptor in the development and progression of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.494178

Secondary hormonal therapy for prostate cancer: what lies on the horizon?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.494178

Chemistry and structural biology of androgen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.494178

P450-dependent enzymes as targets for prostate cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.494178

CYP17 inhibition as a hormonal strategy for prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.494178

A randomized, phase II trial of ketoconazole plus alendronate versus ketoconazole alone in patients with androgen independent prostate cancer and bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.494178

Failure of hormone therapy in prostate cancer involves systematic restoration of androgen responsive genes and activation of rapamycin sensitive signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.494178

Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.494178

Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.494178

Mechanisms of prostate cancer progression to androgen independence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.494178

Molecular determinants of resistance to antiandrogen therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.494178

Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.494178

Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.494178

A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.494178

Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.494178

Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.494178

Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.494178

A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.494178

Androgen receptor (AR) coregulators: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.494178

Site-specific androgen receptor serine phosphorylation linked to epidermal growth factor-dependent growth of castration-recurrent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.494178

Ras signaling in prostate cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.494178

DHT Concentrations in Human Prostate Cancer Tissue*

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.494178

Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.494178

Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.494178

Mechanism of StAR's regulation of mitochondrial cholesterol import

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.494178

Overview of dehydroepiandrosterone biosynthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.494178

The regulation of 17,20 lyase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.494178

5alpha-androstane-3alpha,17beta-diol is formed in tammar wallaby pouch young testes by a pathway involving 5alpha-pregnane-3alpha,17alpha-diol-20-one as a key intermediate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.494178

5α-reduced C21 steroids are substrates for human cytochrome P450c17

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.494178

Integrated view on 17beta-hydroxysteroid dehydrogenases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.494178

Human 17beta-hydroxysteroid dehydrogenases types 1, 2, and 3 catalyze bi-directional equilibrium reactions, rather than unidirectional metabolism, in HEK-293 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.494178

Control of secretion and the function of C19-delta 5-steroids of the human adrenal gland

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.494178

The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.494178

Delta5-androstenediol is a natural hormone with androgenic activity in human prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.494178

Does DHEA exert direct effects on androgen and estrogen receptors, and does it promote or prevent prostate cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.494178

Human 3 beta-hydroxysteroid dehydrogenase/delta 5----4isomerase from placenta: expression in nonsteroidogenic cells of a protein that catalyzes the dehydrogenation/isomerization of C21 and C19 steroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.494178

Molecular biology of the 3beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase gene family

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.494178

Reactivation of androgen receptor-regulated TMPRSS2:ERG gene expression in castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.494178

Steroidogenesis inhibitors alter but do not eliminate androgen synthesis mechanisms during progression to castration-resistance in LNCaP prostate xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.494178

Androgen biosynthetic pathways in the human prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.494178

The key role of 17 beta-hydroxysteroid dehydrogenases in sex steroid biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.494178

Steroid hormone transforming aldo-keto reductases and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.494178

The role of 5alpha-reduction in steroid hormone physiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.494178

Steroid 5 alpha-reductase: two genes/two enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.494178

Structural and biochemical properties of cloned and expressed human and rat steroid 5 alpha-reductases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.494178

Deletion of steroid 5 alpha-reductase 2 gene in male pseudohermaphroditism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.494178

Type 1 and type 2 5alpha-reductase expression in the development and progression of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.494178

Differential alterations in 5alpha-reductase type 1 and type 2 levels during development and progression of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.494178

Steroid 5alpha-reductase isozymes I and II in recurrent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.494178

Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.494178

Feed-forward control of prostate growth: dihydrotestosterone induces expression of its own biosynthetic enzyme, steroid 5 alpha-reductase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.494178

Pre-receptor regulation of the androgen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.494178

Human type 3 3alpha-hydroxysteroid dehydrogenase (aldo-keto reductase 1C2) and androgen metabolism in prostate cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.494178

Inactivation of androgens by UDP-glucuronosyltransferases in the human prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.494178

Discovery of the role of dihydrotestosterone in androgen action.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.494178

Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.494178

Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.494178

Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.494178

Steroid hormone receptors in prostate cancer: a hard habit to break?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.494178

Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.494178

Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.494178

Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.494178

Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.494178

Development of a second-generation antiandrogen for treatment of advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.494178

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.494178

Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.494178

Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.494178

17alpha-Hydroxylase/17,20 lyase inhibitor VN/124-1 inhibits growth of androgen-independent prostate cancer cells via induction of the endoplasmic reticulum stress response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.494178

Differences in substrate and inhibitor kinetics of human type 1 and type 2 3beta-hydroxysteroid dehydrogenase are explained by the type 1 mutant, H156Y.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.494178

Termination of early pregnancy by the 3 beta-hydroxysteroid dehydrogenase inhibitor epostane.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.494178

Prostate cancer stromal cells and LNCaP cells coordinately activate the androgen receptor through synthesis of testosterone and dihydrotestosterone from dehydroepiandrosterone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.494178

Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.494178

Aldo-keto reductase (AKR) 1C3: role in prostate disease and the development of specific inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.494178

Type 5 17beta-hydroxysteroid dehydrogenase/prostaglandin F synthase (AKR1C3): role in breast cancer and inhibition by non-steroidal anti-inflammatory drug analogs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.494178

Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.494178

Activity of dutasteride plus ketoconazole in castration-refractory prostate cancer after progression on ketoconazole alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.494178

Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.494178

17β-Hydroxysteroid dehydrogenase 3 deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.494178

10.1517/13543784.2010.494178

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference